… bortezomib combined with dexamethasone and thalidomide in the treatment of autologous
stem cell transplantation (ASCT) in multiple myeloma (… The meta analysis results showed that …

… multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. …
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell …

… 多发性骨髓瘤（multiple myeloma，MM）治疗的历程可分成三个阶段：传统化疗、造血干细胞移植
、新药或新药序贯移植时代。传统化疗的完全缓解（CR）率小于10%，中位总体生存（OS）期仅为…

… To evaluate the effect of autologous stem cell transplantation (ASCT) on treatment response
and survival outcomes in patients with newly diagnosed multiple myeloma (MM) receiving …

… 多发性骨髓瘤（multiple myeloma，MM）是一种克隆性浆细胞异常增殖的恶性疾病，是血液系统
中较为常见的恶性肿瘤，多发于老年人，目前仍无法治愈[1]。十几年来，新药如蛋白酶体抑制剂、…

… treatment studies for relapsed/refractory multiple myeloma … outcomes in patients with multiple
myeloma: a meta-analysis[J]. … plus bortezomib and dexamethasone versus bortezomib and …

… was 50%(1/2) in patients without bortezomib treatment previously, while 11􀆰 11%(1/9) in …
in patients with previously untreated multiple myeloma: an open⁃label phase 1/2 study. Lancet …

… prednisone compared with mel⁃ phalan and prednisone in previously untreated …
bortezomib/prednisone (VP):A ran⁃ domised trial in elderly untreated pa⁃ tients with multiple …

… of renal function in newly diagnosed multiple myeloma（MM）patients with renal inadequacy.
… therapy in previously untreated multiple myeloma (MM) patients with various degrees of …

… duct of randomized prospective controlled trials in Western … to treat patients suffering from
multiple myeloma. Accordingly, … with the proteasome inhibitor bortezomib in treating this clonal …